Related Experiment Video

Updated: Jun 22, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

Recent patents in Toll-like receptor pathways and relevance to cancer

Kevin Kimbro1, Sabrenia Parker

  • 1Emory University, Department of Hematology and Medical Oncology, Atlanta, GA 30322, USA. kskimbr@emory.edu

Recent Patents on Anti-Cancer Drug Discovery
|June 16, 2009
PubMed

Insights

Toll-like receptors (TLRs) are key innate immune sensors. Recent patents highlight TLRs

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Toll-like receptors (TLRs) are critical membrane receptors in the innate immune system, acting as primary sensors for microbial pathogens.
  • Ligand binding to TLRs initiates cellular signaling pathways regulating inflammatory and immune gene expression.
  • Functional and structural diversity of TLRs indicates their significant role in cellular immunity and various medical conditions, including the tumor microenvironment.

Purpose of the Study:

  • To review recently issued patents concerning Toll-like receptors (TLRs).
  • To explore the relevance of these TLR-related patents for developing novel cancer treatments.

Main Methods:

  • Review of recent patent literature focusing on Toll-like receptors (TLRs).
  • Analysis of patent claims and descriptions for therapeutic applications, particularly in oncology.

Main Results:

  • Identification of emerging patent trends in TLR-targeted therapies.
  • Highlighting specific patented strategies for modulating TLRs in cancer treatment.

Conclusions:

  • TLR heterogeneity presents therapeutic opportunities for targeting specific or multiple TLRs.
  • Patented TLR-targeting approaches may offer novel treatment strategies for various cancers and other diseases.

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...